Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aspire Pharma Ltd, Unit 4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, United Kingdom
Tirofiban *50 micrograms/mL Solution for infusion.
* in the following document the abbreviated terms detailed below are used.
*Tirofiban means Tirofiban Solution for Infusion
* Tirofiban Solution will be used when referring to Tirofiban Solution for Infusion i.e. the 250 ml infusion bag.
Pharmaceutical Form |
---|
Tirofiban Solution: Solution for Infusion (250 ml bag) A clear, colourless solution. |
Tirofiban Solution: 1 ml of solution for infusion contains 56 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms tirofiban.
This medicinal product contains 31 mmol (or 715 mg) sodium per bag (250 ml). To be taken into consideration by patients on a controlled sodium diet.
For excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Tirofiban |
Tirofiban is a non-peptidal antagonist of the GP IIb/IIIa receptor, an important platelet surface receptor involved in platelet aggregation. Tirofiban prevents fibrinogen from binding to the GP IIb/IIIa receptor, thus blocking platelet aggregation. |
List of Excipients |
---|
Sodium dihydrogen phosphate dihydrate |
250 ml flexible plastic IV bag with Twist-off port stopper, colourless, 3-layer polypropylene film. It is packed in a pre-printed foil overpouch.
Aspire Pharma Ltd, Unit 4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, United Kingdom
PL 35533/0058
19/10/2019
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.